Top Health Care Stocks
Health care stocks were declining today, with the NYSE Health Care Index receding about 0.3% while shares of health care companies in the S&P 500 were down about 0.6% as a group.
In company news, Omeros Corp ( OMER ) rallied Tuesday after announced plans to begin Phase III testing of its OMS721 drug candidate in patients with atypical hemolytic-uremic syndrome, a genetic disease associated with chronic risk of complement-mediated, systemic thrombotic microangiopathy (aHUS).
OMS721 is the co's human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 program for the treatment of thrombotic microangiopathies. Federal regulators previously designated OMS721 as an orphan drug for the treatment of TMAs and fast-track status for the treatment of aHUS.
Phase III enrollment is expected to begin later this year and will likely include patients currently being treated in the Phase II trial.
OMER shares were up more than 19% at $15.50 apiece, earlier reaching a session high of $16.06 a share.
In other sector news,
(+) BNTC, (+20.1%) Said BB-HB-331, a DNA-directed RNA interference (ddRNAi) therapy targeting the hepatitis B virus - demonstrated robust and durable suppression of HBV in vivo following a single administration.
(-) ACRX, (-7.8%) Reports $10.5 mln Q4 net loss, or $0.24 per share, missing the analyst consensus expecting a $0.16 per share loss. Revenue of $1.7 mln also missed the three-analyst consensus expecting $5.7 mln.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.